A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years
Publication in refereed journal


引用次數
替代計量分析
.

其它資訊
摘要Intradermal administration of human papillomavirus (HPV) vaccines could be dose-sparing and cost-saving. This pilot randomized study assessed Cervarix (R) and Gardasil (R) administered either intramuscularly or intradermally, in different doses (full-dose or reduced to 20%) by different methods (needle and syringe or PharmaJet needle-free jet injection device). Following an initial reactogenicity study of 10 male subjects, sexually naive women aged 18-26 years were randomized to the eight study groups to receive vaccine at 0, 2 and 6 months. 42 female subjects were enrolled and complete data were available for 40 subjects. Intradermal administration of either vaccine raised no safety concerns but was more reactogenic than intramuscular administration, although still tolerable. All subjects demonstrated a sero-conversion (titre >= 1:320) by Day 95. Further evaluation of intradermal HPV vaccination and its potential for cost reduction in resource poor settings is warranted. (C) 2013 Elsevier Ltd. All rights reserved.
著者Nelson EAS, Lam HS, Choi KC, Ho WCS, Fung LWE, Cheng FWT, Sung RYT, Royals M, Chan PKS
期刊名稱Vaccine
出版年份2013
月份7
日期25
卷號31
期次34
出版社Elsevier
頁次3452 - 3460
國際標準期刊號0264-410X
電子國際標準期刊號1873-2518
語言英式英語
關鍵詞Human papillomavirus; Intradermal; Vaccine
Web of Science 學科類別Immunology; IMMUNOLOGY; Medicine, Research & Experimental; MEDICINE, RESEARCH & EXPERIMENTAL; Research & Experimental Medicine

上次更新時間 2020-19-09 於 01:32